News | September 02, 2022
The unit has filed 2 Derma products and 1 MDI product.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Company appoints five new independent directors to reconstituted board
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Subscribe To Our Newsletter & Stay Updated
